Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing.

ESMO open - 1 Apr 2023

Paiella S, Azzolina D, Gregori D, Malleo G, Golan T, Simeone D M, Davis M B, Vacca P G, Crovetto A, Bassi C, Salvia R, Biankin A V, Casolino R

Abstract excerpt

BACKGROUND: Germline BRCA1 and BRCA2 mutations (gBRCAm) can inform pancreatic cancer (PC) risk and treatment but most of the available information is derived from white patients. The ethnic and geographic variability of gBRCAm prevalence and of germline BRCA (gBRCA) testing uptake in PC globally is largely unknown. MATERIALS AND METHODS: We carried out a systematic review and prevalence meta-analysis of gBRCA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36822114
DOI: 10.1016/j.esmoop.2023.100881
PMCID: PMC10163165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing.PMID 36822114Read ↗

Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO TrialSemantic proximity Read ↗

Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.Semantic proximity Read ↗

Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer.Semantic proximity Read ↗

Impact of Changing Guidelines on Genetic Testing and Surveillance Recommendations in a Contemporary Cohort of Breast Cancer Survivors with Family History of Pancreatic CancerSemantic proximity Read ↗

Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain.Semantic proximity Read ↗

The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.Semantic proximity Read ↗

Development of a Novel Protocol for Germline Testing in Pancreatic Cancer.Semantic proximity Read ↗

Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variantsSemantic proximity Read ↗

Screening Practices for Breast and Nonbreast Cancers in High-Risk Mutation Carriers.Semantic proximity Read ↗

Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.Semantic proximity Read ↗

Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.